A general method for the synthesis of O-alkyl N,O'-arylphosphoramidates and its application to the synthesis of a transition state analogue for carbamate hydrolysis

Tetrahedron

Volumn 54, Issue 17, 1998, Pages 4223-4242

  Taylor, Scott D ^a   Chen, Mei Jin ^a   Dinaut, A Nicole ^a   Batey, Robert A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACID; DRUG CARRIER; PHOSPHORAMIDIC ACID DERIVATIVE; PRODRUG; TUMOR ANTIGEN;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; PRIORITY JOURNAL; TARGET CELL DESTRUCTION;

EID: 0032560152     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(98)00123-9     Document Type: Article

References (42)

1. 1. The ADAPT approach is an extension of ADEPT (antibody-directed enzyme prodrug therapy) in which non-human enzymes are used instead of catalytic antibodies. However, these enzymes are highly immunogenic in humans. Thus, the focus on human catalytic antibodies. For recent reviews of ADEPT see: Jungheim, L. N.; Sheperd, T. A. Chem. Rev. 1994, 94, 1553 and Adv. Drug Del. Rev. 1996, 22, No.3., K. Bagshawe Ed.
2. 1. The ADAPT approach is an extension of ADEPT (antibody-directed enzyme prodrug therapy) in which non-human enzymes are used instead of catalytic antibodies. However, these enzymes are highly immunogenic in humans. Thus, the focus on human catalytic antibodies. For recent reviews of ADEPT see: Jungheim, L. N.; Sheperd, T. A. Chem. Rev. 1994, 94, 1553 and Adv. Drug Del. Rev. 1996, 22, No.3., K. Bagshawe Ed.
3. 2. Wentworth, P.; Datta, A.; Blakey, D.; Partridge, L. J.; Blackburn, G. M. Proc. Natl. Acad. Sci. USA 1996, 93, 799.
4. 3. The reaction catalyzed by the antibody must not be catalyzed by human enzymes in order to avoid premature formation of the drug.
5. 4. Lerner, R. A.; Benkovic, S. J.; Schultz, P. G. Science 1991, 252, 659.
6. 5. Lerner, R. A.; Benkovic, S. J. BioEssays 1988, 9, 107. See also: Lerner, R. A., Hosp. Prac. 1993, 53.
7. 5. Lerner, R. A.; Benkovic, S. J. BioEssays 1988, 9, 107. See also: Lerner, R. A., Hosp. Prac. 1993, 53.
8. 6. Miyashita, H.; Karaki, Y.; Kikuchi, M.; Fujii, I. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5337.
9. 7. Campbell, D. A.; Gong, B.; Kochersperger, Yonkovich, S.; Gallop, M. A.; Schultz, P. G. J. Amer. Chem. Soc. 1994, 116, 2165.
10. 8. Carbamates are stable relatively stable to hydrolysis by most proteases and esterases and have therefore been used extensively as prodrugs and enzyme inhibitors. See references 9 and 1.
11. 9. Kato, M.; Agha, B. J.; Abdul-Rakheem, A. K.; Tsuji, K.; Banks, W. R.; Digenis, G. A. J. Enzyme Inhibition 1993, 7, 105.
12. 10. (a) Ma, G. X.; Batey, R. A.; Taylor, S. D.; Hum, G.; Jones, J. B. Syn Commun. 1997, 27, 2445.
13. (b) The prodrug system described in Scheme 1 is very similar to the self-immolative prodrug linkage developed by Katzenellenbogen and coworkers. See: Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. J. Med. Chem. 1981, 24, 479.
14. 11. Wentworth, P.; Datta, A.; Smith, S.; Marshall, A.; Partridge, L. J.; Blackburn, G. M. J. Am. Chem. Soc. 1997, 119, 2315.
15. 12. Van Vranken, D. L.; Panomitros, D.; Schultz, P. G. Tetrahedron Lett. 1994, 35, 3873.
16. 13. Tawfik, D. S.; Zemel, R. R.; Arad-Yellin, R.; Green, B. S.; Eshhar, Z. Biochemistry 1990, 29, 9916. Liotta, L. J.; Benkovic, P. A.; Miller, G. P. Benkovic, S. J. J. Am. Chem. Soc. 1993, 115, 350.
17. 13. Tawfik, D. S.; Zemel, R. R.; Arad-Yellin, R.; Green, B. S.; Eshhar, Z. Biochemistry 1990, 29, 9916. Liotta, L. J.; Benkovic, P. A.; Miller, G. P. Benkovic, S. J. J. Am. Chem. Soc. 1993, 115, 350.
18. 14. For an overview of methods for synthesizing this class of compounds see: Kosalopoff, G. M.; Maier, L. "Organic Phosphorus Compounds" New York, Wiley Interscience 1972. Chp 16.
19. 15. These reagents are prepared using phosphorous oxychloride. By purifying the initial O-phenylphosphoric dichloride or N-phenylphosphoramidic dichloride derivative (rather than reacting the aniline, phenolic and alcohol derivatives consecutively with phosphorus oxychloride) subsequent reactions proceed much cleaner and complex mixtures of products are, to a certain extent, avoided. Alkyldichlorophosphates, such as methyldichlorophosphate, are not commonly used as starting materials due to loss of the alkyl group during the synthesis.
20. 16. Martin, S. F.; Josey, J. A.; Wong, Y-L.; Dean, D. W. J. Org. Chem. 1994, 59, 4805.
21. 17. Martin, S. F.; Wong, Y-L.; Wagman, A. S., J. Org. Chem. 1994, 59, 4821.
22. 18. Tawfik, D. S.; Zemel, R. R.; Arad-Yellin, R.; Green, B. S.; Eshar, Z. Biochemistry 1990, 29, 9916.
23. 19. Bannworth, W.; Trzeciak, A. Helv. Chim. Acta 1987, 70, 175.
24. 20. Clarke, V. M.; Kirby, G. W.; Toss, A. J. Chem. Soc. 1958, 3039.
25. 21. Dilaris, I. Chem. Ber. 1958, 91, 833.
26. 2 but lower yields were obtained.
27. 23. McKenna, C. E.; Higa, M. T.; Cheung, N. H.; McKenna, M-C. Tetrahedron Lett. 1977, 155.
28. 24. Sieber, P. Helv. Chim. Acta 1977, 60, 2711.
29. 25. Diezel, R. Tetrahedron Lett. 1987, 28, 4371.
30. 26. We had initially avoided this protecting group since we were concerned of the possibility that the nucleophile required for its removal would also cause loss of the benzyl protecting group from the phosphate.
31. 27. Tijssen, P. "Practice and Theory of Enzyme Immunoassays" Elsevier, New York, 1985, Chp. 12.
32. 28. Competition experiments with various activated esters of N-protected amino acids have shown that the Pfp esters are more reactive than the NHS esters for peptide bond formation. See: Hudson, D. Peptide Res. 1990, 3, 51.
33. 29. Zhang, H. X.; Guibe, F.; Balavione, G. Tetrahedron Lett. 1988, 29, 623.
34. 30. DCC is the coupling agent most commonly employed for forming Pfp esters. See: Kisfaludy, L.; Schon, I. Synthesis, 1983, 325.
35. 31. Antibody screening and production is being performed by Prof. William Crosby at the Plant Biotechnology Institute, Saskatoon, Canada. For a description of the phage display library see reference 32.
36. 32. Griffiths, A. D.; Williams, S. C.; Hartley, O.; Tomlinson, I. M.; Waterhouse, P.; Crosby, W. L.; Konterman, R. E.; Jones, P. T.; Low, N. M.; Allison, T. J.; Prospero, T. D.; Hoogenboom, H. R.; Nissim, A.; Cox, J. P. L.; Harrison, J. L.; Zaccolo, M.; Gherardi, E.; Winter, G. EMBO 1994, 13, 3245.
37. 33. Ogilvie, K.; Theriault, N. Y.; Seifert, J-M.; Pon, R. T.; Nemer, M. J. Can. J. Chem. 1980, 58, 2686.
38. 34. Kutzbach, C.; Jaenicke, L. Justus Liebigs Ann. Chem. 1966, 692, 26.
39. 35. Okada, K. J. Mol. Struct. 1996, 380, 223.
40. 36. Ryan, A. J.; Vermeulen, M. J. N.; Baker, B. R. J. Med. Chem. 1970, 13, 1140.
41. 37. Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.K.; Gartner, F.H.; Provenzano, M.D.; Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Anal. Biochem. 1985, 150, 76-85.
42. 38. Habeeb, A.F.S.A. Anal. Biochem. 1966, 14, 328.